Journal ArticleOPEN ACCESS

Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?

  • Leonetti A
  • Facchinetti F
  • Tiseo M
Annals of Translational Medicine (2018) 6(S2) S110-S110
DOI: 10.21037/atm.2018.11.69
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

In the last 10 years, the prognosis of advanced non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor ( EGFR ) mutations has dramatically improved, since the introduction of selective EGFR-tyrosine kinase inhibitors (TKIs).

Cite

CITATION STYLE

APA

Leonetti, A., Facchinetti, F., & Tiseo, M. (2018). Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? Annals of Translational Medicine, 6(S2), S110–S110. https://doi.org/10.21037/atm.2018.11.69

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free